Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 172

1.

Plasma total homocysteine and carotid intima-media thickness in type 1 diabetes: a prospective study.

Basu A, Jenkins AJ, Stoner JA, Thorpe SR, Klein RL, Lopes-Virella MF, Garvey WT, Lyons TJ; DCCT/EDIC Research Group.

Atherosclerosis. 2014 Sep;236(1):188-195. doi: 10.1016/j.atherosclerosis.2014.07.001. Epub 2014 Jul 15.

2.

Mice deficient in both Mn superoxide dismutase and glutathione peroxidase-1 have increased oxidative damage and a greater incidence of pathology but no reduction in longevity.

Zhang Y, Ikeno Y, Qi W, Chaudhuri A, Li Y, Bokov A, Thorpe SR, Baynes JW, Epstein C, Richardson A, Van Remmen H.

J Gerontol A Biol Sci Med Sci. 2009 Dec;64(12):1212-20. doi: 10.1093/gerona/glp132. Epub 2009 Sep 23.

3.

Succination of thiol groups in adipose tissue proteins in diabetes: succination inhibits polymerization and secretion of adiponectin.

Frizzell N, Rajesh M, Jepson MJ, Nagai R, Carson JA, Thorpe SR, Baynes JW.

J Biol Chem. 2009 Sep 18;284(38):25772-81. doi: 10.1074/jbc.M109.019257. Epub 2009 Jul 10.

4.

AGE-modified albumin containing infusion solutions boosts septicaemia and inflammation in experimental peritonitis.

Humpert PM, Lukic IK, Thorpe SR, Hofer S, Awad EM, Andrassy M, Deemer EK, Kasper M, Schleicher E, Schwaninger M, Weigand MA, Nawroth PP, Bierhaus A.

J Leukoc Biol. 2009 Sep;86(3):589-97. doi: 10.1189/jlb.1008646. Epub 2009 Apr 28.

5.

Succination of proteins by fumarate: mechanism of inactivation of glyceraldehyde-3-phosphate dehydrogenase in diabetes.

Blatnik M, Thorpe SR, Baynes JW.

Ann N Y Acad Sci. 2008 Apr;1126:272-5. doi: 10.1196/annals.1433.047.

6.

Cross-sectional associations of C-reactive protein with vascular risk factors and vascular complications in the DCCT/EDIC cohort.

Jenkins AJ, Rothen M, Klein RL, Moller K, Eldridge L, Zheng D, Durazo-Arvizu R, McGee D, Lackland D, Thorpe SR, Garvey WT, Lyons TJ; DCCT/EDIC Research Group.

J Diabetes Complications. 2008 May-Jun;22(3):153-63. doi: 10.1016/j.jdiacomp.2007.02.003. Epub 2008 Apr 16.

PMID:
18413218
7.

Increased methionine sulfoxide content of apoA-I in type 1 diabetes.

Brock JW, Jenkins AJ, Lyons TJ, Klein RL, Yim E, Lopes-Virella M, Carter RE; (DCCT/EDIC) Research Group, Thorpe SR, Baynes JW.

J Lipid Res. 2008 Apr;49(4):847-55. doi: 10.1194/jlr.M800015-JLR200. Epub 2008 Jan 17.

8.

Inhibition of NADPH oxidase prevents advanced glycation end product-mediated damage in diabetic nephropathy through a protein kinase C-alpha-dependent pathway.

Thallas-Bonke V, Thorpe SR, Coughlan MT, Fukami K, Yap FY, Sourris KC, Penfold SA, Bach LA, Cooper ME, Forbes JM.

Diabetes. 2008 Feb;57(2):460-9. Epub 2007 Oct 24.

10.

Succination of protein thiols during adipocyte maturation: a biomarker of mitochondrial stress.

Nagai R, Brock JW, Blatnik M, Baatz JE, Bethard J, Walla MD, Thorpe SR, Baynes JW, Frizzell N.

J Biol Chem. 2007 Nov 23;282(47):34219-28. Epub 2007 Aug 28.

11.

Advanced glycation end products and the absence of premature atherosclerosis in glycogen storage disease Ia.

den Hollander NC, Mulder DJ, Graaff R, Thorpe SR, Baynes JW, Smit GP, Smit AJ.

J Inherit Metab Dis. 2007 Nov;30(6):916-23. Epub 2007 Jun 14.

12.

Confocal Raman microscopy can quantify advanced glycation end product (AGE) modifications in Bruch's membrane leading to accurate, nondestructive prediction of ocular aging.

Glenn JV, Beattie JR, Barrett L, Frizzell N, Thorpe SR, Boulton ME, McGarvey JJ, Stitt AW.

FASEB J. 2007 Nov;21(13):3542-52. Epub 2007 Jun 12.

PMID:
17567569
13.

Detection and identification of arginine modifications on methylglyoxal-modified ribonuclease by mass spectrometric analysis.

Brock JW, Cotham WE, Thorpe SR, Baynes JW, Ames JM.

J Mass Spectrom. 2007 Jan;42(1):89-100.

PMID:
17143934
14.

Formation of methionine sulfoxide during glycoxidation and lipoxidation of ribonuclease A.

Brock JW, Ames JM, Thorpe SR, Baynes JW.

Arch Biochem Biophys. 2007 Jan 15;457(2):170-6. Epub 2006 Nov 2.

15.

Combination therapy with the advanced glycation end product cross-link breaker, alagebrium, and angiotensin converting enzyme inhibitors in diabetes: synergy or redundancy?

Coughlan MT, Thallas-Bonke V, Pete J, Long DM, Gasser A, Tong DC, Arnstein M, Thorpe SR, Cooper ME, Forbes JM.

Endocrinology. 2007 Feb;148(2):886-95. Epub 2006 Nov 16.

PMID:
17110423
16.

Advanced glycation end-products and methionine sulphoxide in skin collagen of patients with type 1 diabetes.

Yu Y, Thorpe SR, Jenkins AJ, Shaw JN, Sochaski MA, McGee D, Aston CE, Orchard TJ, Silvers N, Peng YG, McKnight JA, Baynes JW, Lyons TJ; DCCT/EDIC Research Group.

Diabetologia. 2006 Oct;49(10):2488-98. Epub 2006 Aug 29.

PMID:
16955213
17.

S-(2-Succinyl)cysteine: a novel chemical modification of tissue proteins by a Krebs cycle intermediate.

Alderson NL, Wang Y, Blatnik M, Frizzell N, Walla MD, Lyons TJ, Alt N, Carson JA, Nagai R, Thorpe SR, Baynes JW.

Arch Biochem Biophys. 2006 Jun 1;450(1):1-8. Epub 2006 Mar 22.

PMID:
16624247
18.

Skin autofluorescence, a measure of cumulative metabolic stress and advanced glycation end products, predicts mortality in hemodialysis patients.

Meerwaldt R, Hartog JW, Graaff R, Huisman RJ, Links TP, den Hollander NC, Thorpe SR, Baynes JW, Navis G, Gans RO, Smit AJ.

J Am Soc Nephrol. 2005 Dec;16(12):3687-93. Epub 2005 Nov 9.

19.

Tissue-specific variation in glycation of proteins in diabetes: evidence for a functional role of amadoriase enzymes.

Brown SM, Smith DM, Alt N, Thorpe SR, Baynes JW.

Ann N Y Acad Sci. 2005 Jun;1043:817-23. Review.

PMID:
16037309
20.

Dietary bread crust advanced glycation end products bind to the receptor for AGEs in HEK-293 kidney cells but are rapidly excreted after oral administration to healthy and subtotally nephrectomized rats.

Somoza V, Lindenmeier M, Hofmann T, Frank O, Erbersdobler HF, Baynes JW, Thorpe SR, Heidland A, Zill H, Bek S, Huber J, Weigle T, Scheidler S, Busch AE, Sebeková K.

Ann N Y Acad Sci. 2005 Jun;1043:492-500.

PMID:
16037271
21.

Renal effects of oral maillard reaction product load in the form of bread crusts in healthy and subtotally nephrectomized rats.

Sebeková K, Hofmann T, Boor P, Sebeková K Jr, Ulicná O, Erbersdobler HF, Baynes JW, Thorpe SR, Heidland A, Somoza V.

Ann N Y Acad Sci. 2005 Jun;1043:482-91.

PMID:
16037270
22.

Lipid-derived modifications of plasma proteins in experimental and human diabetes.

Januszewski AS, Jenkins AJ, Baynes JW, Thorpe SR.

Ann N Y Acad Sci. 2005 Jun;1043:404-12.

PMID:
16037262
23.

Glycation does not alter LDL-induced secretion of tissue plasminogen activator and plasminogen activator inhibitor-1 from human aortic endothelial cells.

Klein RL, Semler AJ, Baynes JW, Thorpe SR, Lyons TJ, Jenkins AJ.

Ann N Y Acad Sci. 2005 Jun;1043:379-89.

PMID:
16037259
24.

The immunogenicity of modified lipoproteins.

Lopes-Virella MF, Thorpe SR, Derrick MB, Chassereau C, Virella G.

Ann N Y Acad Sci. 2005 Jun;1043:367-78. Review.

PMID:
16037258
25.

Simple noninvasive measurement of skin autofluorescence.

Meerwaldt R, Links T, Graaff R, Thorpe SR, Baynes JW, Hartog J, Gans R, Smit A.

Ann N Y Acad Sci. 2005 Jun;1043:290-8.

PMID:
16037251
26.

Proteomic method for the quantification of methionine sulfoxide.

Brock JW, Cotham WC, Ames JM, Thorpe SR, Baynes JW.

Ann N Y Acad Sci. 2005 Jun;1043:284-9.

PMID:
16037250
27.

Effect of glucose concentration on formation of AGEs in erythrocytes in vitro.

Nagai R, Deemer EK, Brock JW, Thorpe SR, Baynes JW.

Ann N Y Acad Sci. 2005 Jun;1043:146-50.

PMID:
16037233
28.

The role of AGEs and AGE inhibitors in diabetic cardiovascular disease.

Thomas MC, Baynes JW, Thorpe SR, Cooper ME.

Curr Drug Targets. 2005 Jun;6(4):453-74. Review.

PMID:
16026265
29.

Renal accumulation of pentosidine in non-diabetic proteinuria-induced renal damage in rats.

Waanders F, Greven WL, Baynes JW, Thorpe SR, Kramer AB, Nagai R, Sakata N, van Goor H, Navis G.

Nephrol Dial Transplant. 2005 Oct;20(10):2060-70. Epub 2005 Jun 14.

PMID:
15956058
30.

Modulation of soluble receptor for advanced glycation end products by angiotensin-converting enzyme-1 inhibition in diabetic nephropathy.

Forbes JM, Thorpe SR, Thallas-Bonke V, Pete J, Thomas MC, Deemer ER, Bassal S, El-Osta A, Long DM, Panagiotopoulos S, Jerums G, Osicka TM, Cooper ME.

J Am Soc Nephrol. 2005 Aug;16(8):2363-72. Epub 2005 Jun 1.

31.

Chemical modification of proteins during peroxidation of phospholipids.

Januszewski AS, Alderson NL, Jenkins AJ, Thorpe SR, Baynes JW.

J Lipid Res. 2005 Jul;46(7):1440-9. Epub 2005 Apr 1.

32.

Impaired retinal angiogenesis in diabetes: role of advanced glycation end products and galectin-3.

Stitt AW, McGoldrick C, Rice-McCaldin A, McCance DR, Glenn JV, Hsu DK, Liu FT, Thorpe SR, Gardiner TA.

Diabetes. 2005 Mar;54(3):785-94.

33.

Development of capture assays for different modifications of human low-density lipoprotein.

Virella G, Derrick MB, Pate V, Chassereau C, Thorpe SR, Lopes-Virella MF.

Clin Diagn Lab Immunol. 2005 Jan;12(1):68-75.

34.

Advanced glycation and advanced lipoxidation: possible role in initiation and progression of diabetic retinopathy.

Stitt AW, Frizzell N, Thorpe SR.

Curr Pharm Des. 2004;10(27):3349-60. Review.

PMID:
15544520
35.

Substrates modified by advanced glycation end-products cause dysfunction and death in retinal pericytes by reducing survival signals mediated by platelet-derived growth factor.

Stitt AW, Hughes SJ, Canning P, Lynch O, Cox O, Frizzell N, Thorpe SR, Cotter TG, Curtis TM, Gardiner TA.

Diabetologia. 2004 Oct;47(10):1735-46. Epub 2004 Oct 22.

PMID:
15502926
36.

The effects of valsartan on the accumulation of circulating and renal advanced glycation end products in experimental diabetes.

Forbes JM, Thomas MC, Thorpe SR, Alderson NL, Cooper ME.

Kidney Int Suppl. 2004 Nov;(92):S105-7. Review.

37.

Proteomic analysis of arginine adducts on glyoxal-modified ribonuclease.

Cotham WE, Metz TO, Ferguson PL, Brock JW, Hinton DJ, Thorpe SR, Baynes JW, Ames JM.

Mol Cell Proteomics. 2004 Dec;3(12):1145-53. Epub 2004 Sep 17.

38.

Effect of antioxidants and ACE inhibition on chemical modification of proteins and progression of nephropathy in the streptozotocin diabetic rat.

Alderson NL, Chachich ME, Frizzell N, Canning P, Metz TO, Januszewski AS, Youssef NN, Stitt AW, Baynes JW, Thorpe SR.

Diabetologia. 2004 Aug;47(8):1385-95. Epub 2004 Jul 28.

PMID:
15309289
39.

In vivo glycated low-density lipoprotein is not more susceptible to oxidation than nonglycated low-density lipoprotein in type 1 diabetes.

Jenkins AJ, Thorpe SR, Alderson NL, Hermayer KL, Lyons TJ, King LP, Chassereau CN, Klein RL.

Metabolism. 2004 Aug;53(8):969-76.

PMID:
15281003
40.

Definition of the immunogenic forms of modified human LDL recognized by human autoantibodies and by rabbit hyperimmune antibodies.

Virella G, Thorpe SR, Alderson NL, Derrick MB, Chassereau C, Rhett JM, Lopes-Virella MF.

J Lipid Res. 2004 Oct;45(10):1859-67. Epub 2004 Jul 16.

41.

Simple non-invasive assessment of advanced glycation endproduct accumulation.

Meerwaldt R, Graaff R, Oomen PHN, Links TP, Jager JJ, Alderson NL, Thorpe SR, Baynes JW, Gans ROB, Smit AJ.

Diabetologia. 2004 Jul;47(7):1324-1330. doi: 10.1007/s00125-004-1451-2. Epub 2004 Jul 9.

PMID:
15243705
42.

Advanced glycation end product interventions reduce diabetes-accelerated atherosclerosis.

Forbes JM, Yee LT, Thallas V, Lassila M, Candido R, Jandeleit-Dahm KA, Thomas MC, Burns WC, Deemer EK, Thorpe SR, Cooper ME, Allen TJ.

Diabetes. 2004 Jul;53(7):1813-23. Erratum in: Diabetes. 2006 Mar;55(3):862. Thorpe, Susan M [corrected to Thorpe, Susan R].

43.

Chemical modification of muscle protein in diabetes.

Alt N, Carson JA, Alderson NL, Wang Y, Nagai R, Henle T, Thorpe SR, Baynes JW.

Arch Biochem Biophys. 2004 May 15;425(2):200-6.

PMID:
15111128
44.

Life-long reduction in MnSOD activity results in increased DNA damage and higher incidence of cancer but does not accelerate aging.

Van Remmen H, Ikeno Y, Hamilton M, Pahlavani M, Wolf N, Thorpe SR, Alderson NL, Baynes JW, Epstein CJ, Huang TT, Nelson J, Strong R, Richardson A.

Physiol Genomics. 2003 Dec 16;16(1):29-37.

PMID:
14679299
45.

Maillard reaction products in tissue proteins: new products and new perspectives.

Thorpe SR, Baynes JW.

Amino Acids. 2003 Dec;25(3-4):275-81. Epub 2003 Jul 29. Review.

PMID:
14661090
46.

Mass spectrometric analysis of glucose-modified ribonuclease.

Cotham WE, Hinton DJ, Metz TO, Brock JW, Thorpe SR, Baynes JW, Ames JM.

Biochem Soc Trans. 2003 Dec;31(Pt 6):1426-7.

PMID:
14641080
47.

Role of lipids in chemical modification of proteins and development of complications in diabetes.

Januszewski AS, Alderson NL, Metz TO, Thorpe SR, Baynes JW.

Biochem Soc Trans. 2003 Dec;31(Pt 6):1413-6. Review.

PMID:
14641077
48.

Proteomic analysis of the site specificity of glycation and carboxymethylation of ribonuclease.

Brock JW, Hinton DJ, Cotham WE, Metz TO, Thorpe SR, Baynes JW, Ames JM.

J Proteome Res. 2003 Sep-Oct;2(5):506-13.

PMID:
14582647
49.

Pyridoxamine, an inhibitor of advanced glycation and lipoxidation reactions: a novel therapy for treatment of diabetic complications.

Metz TO, Alderson NL, Thorpe SR, Baynes JW.

Arch Biochem Biophys. 2003 Nov 1;419(1):41-9. Review.

PMID:
14568007
50.

Supplemental Content

Loading ...
Support Center